title: Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: A KIMS-based study.
abstract: OBJECTIVE
  To characterize further the clinical manifestations and the efficacy of growth hormone (GH) replacement therapy in patients with adult-onset growth hormone deficiency (GHD) reported in the KIMS (Pfizer's international metabolic database) as caused by traumatic brain injury (TBI) and to compare them with nonirradiated patients whose GHD was due to a nonfunctioning pituitary adenoma (NFPA).
  
  
  METHODS
  Observational study.
  
  
  METHODS
  Subjects selected from the KIMS database.
  
  
  METHODS
  Fifty-one patients with GHD resulting from TBI and 688 patients with GHD resulting from NFPA. Both groups were selected from the KIMS and had adult-onset GHD with GH replacement therapy only after KIMS entry and before and after KIMS entry.
  
  
  METHODS
  Not applicable.
  
  
  METHODS
  Age, body mass index, age at disease onset, age at disease diagnosis, age at KIMS entry, final height, GH peak at testing, GH replacement dose, routine biochemical analysis, clinical manifestations of disease, and quality of life measurements.
  
  
  RESULTS
  Patients with TBI were significantly younger at study entry and were younger both at pituitary disease onset and at GHD diagnosis, but they showed a significant delay in treatment. When comparing patients not treated with GH before entering in the KIMS, patients with TBI were significantly shorter (167.2+/-1.7 cm) than those with NFPA (171.6+/-0.4 cm) in final height. TBI patients had lower GH reserves than NFPA patients, and although the latter group experienced more positive changes, both groups benefited from GH replacement therapy.
  
  
  CONCLUSIONS
  Patients with GHD due to TBI showed a significant reduction in height and a reduction in pituitary GH reserve and were diagnosed and treated with inappropriate delay.
authors.affiliation: Department of Medicine, Endocrine Section, School of Medicine and Complejo Hospitalario Universitario de Santiago, University of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Felipe F
authors.initials: FF
authors.lastname: Casanueva
authors.forename: Alfonso
authors.initials: A
authors.lastname: Leal
authors.forename: Maria
authors.initials: M
authors.lastname: Koltowska-Häggström
authors.forename: Peter
authors.initials: P
authors.lastname: Jonsson
authors.forename: Miklós I
authors.initials: MI
authors.lastname: Góth
mesh_terms: D000328:Adult; D015992:Body Mass Index; D001930:Brain Injuries / Q000150:complications / Q000378:metabolism*; D016208:Databases, Factual; D005260:Female; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D017891:Pharmacoepidemiology; D010900:Pituitary Diseases / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism; D011788:Quality of Life
chemical_list: D019382:Human Growth Hormone